96740-92-0|3-Fluoro-4-(hydroxymethyl)phenol| Ambeed

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

{[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

Quality Control of [ 96740-92-0 ] Purity: 95% SDS Specification

COA

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

NMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

CNMR

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

HPLC

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

LC-MS

Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.

1-2 Day Shipping
High Quality
Technical Support

Product Details of [ 96740-92-0 ]

CAS No. :	96740-92-0
Formula :	C₇H₇FO₂
M.W :	142.13
SMILES Code :	OC1=CC=C(CO)C(F)=C1
MDL No. :	MFCD06797932
Boiling Point :	No data available
InChI Key :	IXBHZARBEOBOTB-UHFFFAOYSA-N
Pubchem ID :	53939912

Safety of [ 96740-92-0 ]

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319
Precautionary Statements:	P261-P305+P351+P338

Computational Chemistry of [ 96740-92-0 ] Show Less

Physicochemical Properties

Num. heavy atoms	10
Num. arom. heavy atoms	6
Fraction Csp3	0.14
Num. rotatable bonds	1
Num. H-bond acceptors	3.0
Num. H-bond donors	2.0
Molar Refractivity	34.55
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	40.46 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	1.18
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	0.78
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	1.29
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.31
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.62
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.24

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-1.59
Solubility	3.65 mg/ml ; 0.0257 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-1.21
Solubility	8.76 mg/ml ; 0.0616 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-1.91
Solubility	1.76 mg/ml ; 0.0124 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	Yes
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.61 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12'782'590 molecules and tested on 40 external molecules (r² = 0.94)	1.03

Application In Synthesis of [ 96740-92-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 96740-92-0 ]

[ 96740-92-0 ] Synthesis Path-Downstream 1~24

1
[ 105-36-2 ]
[ 96740-92-0 ]
[ 214554-35-5 ]

References: [1]Tetrahedron Letters,1998,vol. 39,p. 7193 - 7196.

2
[ 65145-13-3 ]
[ 96740-92-0 ]

Yield	Reaction Conditions	Operation in experiment
	With lithium aluminium tetrahydride; In tetrahydrofuran; at 0 - 20℃; for 3h;Inert atmosphere;	Intermediate 16[113]Synthesis of 3-fluoro-4-(hydroxymethyl)phenol[114] [115]5 g of 2-fluoro-4-hydroxybenzoicacid was dissolved in 100 mL of THF with stirring in a 250 mL flask under anitrogen atmosphere. 2.43 g of LAH was added dropwise to the solution at 0 , and the mixture was stirred at room temperature for3 hours or more. The reaction material was washed with 200 mL of EA and 200 mLof 10% NaOH aqueous solution to remove LAH and extracted with 200 mL of EA. Theextract was dried with anhydrous magnesium sulfate, concentrated and thencrystallized using EA and diethyl ether, thereby obtaining the title compound.[116]1H NMR (400, CDCl3) : 7.26 (1H, t), 6.62(2H, m), 4.49 (1H, s), 4.68 (2H, d), 1.58 (3H, s).

References: [1]Tetrahedron Letters,1998,vol. 39,p. 7193 - 7196.
[2]Patent: WO2013/105753,2013,A1 .Location in patent: Paragraph 112; 113; 114; 115; 116.
[3]ChemMedChem,2013,vol. 8,p. 779 - 799.

3
[ 96740-92-0 ]
[ 214554-36-6 ]

References: [1]Tetrahedron Letters,1998,vol. 39,p. 7193 - 7196.

4
[ 96740-92-0 ]
[Butyl-(2-oxo-2H-chromene-3-carbonyl)-amino]-acetic acid [ No CAS ]

References: [1]Tetrahedron Letters,1998,vol. 39,p. 7193 - 7196.

5
2-fluoro-4-propoxybenzoic acid [ No CAS ]
[ 96740-92-0 ]

References: [1]Tetrahedron Letters,1998,vol. 39,p. 7193 - 7196.

6
[ 348-27-6 ]
[ 96740-92-0 ]

References: [1]Chemistry Letters,2008,vol. 37,p. 436 - 437.
[2]Journal of Medicinal Chemistry,2015,vol. 57,p. 8984 - 8998.

7
[ 79-03-8 ]
[ 96740-92-0 ]
[ 1037776-15-0 ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In ethyl acetate; at 0℃; for 1.33333h;	Preparation 1: 3-Fluoro-4-hydroxymethylphenyl propionate. NEt3 (1.1 mL, 7.9 mmol) was added to a stirred solution of <strong>[96740-92-0]2-fluoro-4-hydroxybenzyl alcohol</strong> (1.10 g, 7.9 mmol) in EtOAc (13 mL) at 00C. The reaction was then treated dropwise with a solution of EtCOCl (680 muL, 7.9 mmol) in EtOAc (6 mL) over 10 min. After 70 min, Et2O was added, then the solution was washed with H2O (4 mL) and brine (4 mL), before being dried (Na2SO/(). Filtration, solvent evaporation, & column chromatography (IH-EtOAc, 1 :1) provided the title compound: deltaH (CDCl3) 1.30 (t, 3H), 1.76 (t, IH), 2.61 (q, 2H), 4.79 (d, 2H), 6.88-6.97 (m, 2H), 7.45 (t, IH).

References: [1]Patent: WO2008/81206,2008,A1 .Location in patent: Page/Page column 12.

8
[ 96740-92-0 ]
[ 5188-07-8 ]
[ 1037776-16-1 ]

Yield	Reaction Conditions	Operation in experiment
		General procedure: Intermediate 17[118]Synthesis of 3-fluoro-4-(methylthiomethyl)phenol[119] [120]1.8 g of 3-fluoro-4-(hydroxymethyl)phenylwas dissolved in 100 mL of THF with stirring in a 250 mL flask under anitrogen atmosphere. 3.57 g of triphenylphosphine and 2.4 g ofN-bromosuccinimide were added dropwise to the solution at 0 , and the mixture was stirred at room temperature for1 hour or more. After completion of the reaction, 1.9 g of sodium thiomethoxidewas added dropwise to the reaction solution which was then stirred at roomtemperature for 12 hours or more. After completion of the reaction, 100 mL of1N HCl aqueous solution was added to the reaction solution which was thenextracted with 100 mL of EA. The extract was dried with anhydrous magnesiumsulfate, concentrated and then purified by silica column chromatography, therebyobtaining the title compound.[121]1H NMR (400, CDCl3) : 7.14 (1H, t), 6.58(2H, m), 3.66 (2H, s), 2.05 (3H, s).

References: [1]Patent: WO2013/105753,2013,A1 .Location in patent: Paragraph 117; 118; 119; 120; 121.

9
[ 100-39-0 ]
[ 96740-92-0 ]
[ 504414-33-9 ]